Drug Profile

ACT 101

Alternative Names: ACT-101

Latest Information Update: 11 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alpha Cancer Technologies
Class Recombinant proteins
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myasthenia gravis
New Molecular Entity No

Highest Development Phases

Phase I Inflammatory bowel diseases; Multiple sclerosis; Myasthenia gravis; Thyroiditis

Most Recent Events

11 Mar 2025 ACT 101 is still in phase I trials for Myasthenia gravis in USA (PO) (Alpha Cancer Technologies pipeline, March 2025)
11 Mar 2025 ACT 101 is still in phase I trials for Inflammatory bowel disease in USA (PO) (Alpha Cancer Technologies pipeline, March 2025)
11 Mar 2025 ACT 101 is still in phase I trials for Multiple sclerosis in USA (PO) (Alpha Cancer Technologies pipeline, March 2025)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com